Key result
Adjuvant chemotherapy is linked to prolonged survival after resection only in stage III synovial sarcoma.
Why the study?
Does adjuvant chemotherapy improve overall survival in patients with resectable stage I-III synovial sarcoma?
Population
544 patients with stage I-III synovial sarcoma 2004-2012 undergoing curative-intent resection, identified in…
Comparison
Adjuvant chemotherapy (AC) vs No adjuvant chemotherapy
Design
Cohort
Authors
Loading...
May support adjuvant chemotherapy in stage III synovial sarcoma; leaves open causality and need for randomized confirmation.
Cohort (n=544)
Yes
Does adjuvant chemotherapy improve overall survival in patients with resectable stage I-III synovial sarcoma?
p-value: p=0.033
Adjuvant chemotherapy is associated with prolonged overall survival in stage III resectable synovial sarcoma, but not in lower stages.
Vining et al. (2017) conducted a cohort in Stage I-III synovial sarcoma (n=544). Adjuvant chemotherapy vs. No adjuvant chemotherapy was evaluated on Overall survival (p=0.033). Adjuvant chemotherapy was associated with prolonged overall survival following curative-intent resection in patients with stage III synovial sarcoma (P=0.033), but not in lower stages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: